The company also attracted the rsources of Apollo Health Ventures, Sv health investors’ biotech fund, Dementia discovery fund, Dolby family ventures, Eli Lilly, Foundation for a better world, Mrl ventures fund, and Sanofi ventures
Angelini ventures, a vehicle of Italian pharmaceutical company Angelini Industries for investing in biotech and digital health, said it co-led with Apollo Health Ventures the 39 million US Dollars estension of the Series A round of Therini Bio, a San Francisco – based biotech in the clinical phase that develops immunotherapies for neuroinflammation in diseases caused by vascular dysfunction.
Therini also attracted the resources of, SV Health Investors’ Biotech Fund, Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures e Foundation for a Better World (press release of TheriniBio and Angelini Ventures statement). Such firms also poured money in the first tranche of the round amounting to 36 million for a total of 75 million.
Angelini Ventures recently invested in Singapore’s Nuevocor (see here a previous post by BeBeez), and appointed Fabrizio Calisti, medical director of the fund, for joining the board of Therini Bio as auditor.
Therini Bio addresses the fundamental vascular dysfunction that contributes to neurodegenerative diseases with an innovative approach. The company’s proprietary technology targets inflammatory fibrin epitopes to halt the destructive cascade of neuroinflammation without compromising essential coagulation pathways.
Tara Nickerson, Ph.D., Therini Bio ceo, said: “We are grateful to collaborate with such an important group of investors. Their support allows us to significantly advance our shared vision of offering patients a rational and innovative approach to potentially treating their debilitating conditions, including AD and DME.” The company will invest the raised proceeds in supporting the development of fibrin-targeted immunotherapies for neurodegenerative diseases caused by vascular dysfunction and in conducting advanced phase 1b studies evaluating THN391 for Alzheimer’s disease; continue clinical development for diabetic macular oedema applications; and support the development of a bispecific fibrin/VEGF therapy.
“We are proud to support the mission of Therini Bio. As active investors in the CNS sector, we are excited about Therini’s first selective antibody therapy, which offers a revolutionary pathway to transform the treatment of diseases such as Alzheimer’s and age-related macular oedema (Dme)”, Thomas Thestrup, Ph.D., Senior Principal of Angelini Ventures and deal lead, added.
In January 2025, Angelini Industries joined the 35 million euros Series B round of Belgium’s AgeTech (see here a previous post by BeBeez) and the 20 million Series A round of Danish Neumirna Therapeutics (see a previous post by BeBeez). In March 2025, Angelini Ventures poured money in the 10 million Series A round of German Vantis (see here a previous post by BeBeez).
Angelini Ventures was born in 2022 and set an investment target of 300 million euros (see here a previous post by BeBeez). The fund already allocated 100 million in Cour Pharmaceuticals, Noctrix Health, Nouscom, Avation Medical, Pretzel Therapeutics, Cadence Neuroscience, Freya Biosciences, Neumirna Therapeutics, Nobi, Vantis, and other companies for a total of 19 portfolio assets.
BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Angelini Ventures and its portfolio companies. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager
